ClinicalTrials.gg
RecruitingNCT05508932Updated Feb 24, 2026

Atrial Fibrillation in Beta-Thalassemia

An observational study in Atrial Fibrillation and Thalassemia, sponsored by University Hospital of Ferrara. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University Hospital of Ferrara · Observational

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 252 studies in Atrial Fibrillation with a site in Italy — 44 open to participants now, 64 under way, 2 of them phase 3. Atrial Fibrillation · Italy.

Planned enrollment
54th of 95
350 · median 411
Started
2022
with 12 others
Observational
95 of 252
22 open now
Primary completion
2032-06
later than 62 of 63 live
Registered
183rd of 252
by date

Among the 252 studies in Atrial Fibrillation with a site in Italy, this one is the 54th largest by planned enrollment of the 95 observational ones that give a count, is one of 13 that started in 2022, is one of 95 observational ones, reaches primary completion later than 62 of the 63 other live ones, and was the 183rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

44 of the 252 studies in Atrial Fibrillation with a site in Italy are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Atrial Fibrillation with a site in Italy, or all of them as a file.
02

Study summary

The study aims to evaluate the clinical, laboratory and instrumental differences that exist between beta-thalassemia patients with atrial fibrillation and those not affected by arrhythmia.

Read the detailed description

Observational, retrospective and prospective, single-center study, which involves the collection of clinical, laboratory, electrocardiographic and imaging data of patients with major or intermediate thalassemia who have performed, from 2012 to 2022, or will perform in the next 10 years, a cardiological evaluation at the Cardiology Unit of the University Hospital of Ferrara. Patients will be divided into two groups: thalassemia patients with atrial fibrillation (paroxysmal, persistent or permanent) and thalassemia patients with no history of atrial fibrillation.

The objective of the study is to evaluate whether there is a different prevalence of the characteristics analyzed among these patient populations.

As secondary outcome, the effect of SGLT2-inhibitors (empaglifozin, dapaglifozin, ...) will be evaluated.

03

Conditions studied

  • Atrial Fibrillation
  • Thalassemia

Keywords

  • Atrial Fibrillation
  • Thalassemia
  • Thalassaemia
  • Arrhythmia
  • Hemoglobinopathies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Transfusion-dependent Beta-thalassemia patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Transfusion-dependent Beta-thalassemia;
  2. Follow-Up at the Cardiology Unit of the University Hospital of Ferrara;
  3. performed;
  4. Echocardiogram performed.

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years;
  2. State Of pregnancy;
  3. Inability to give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • Beta-thalassemia

    Patients with Beta-thalassemia undergoing a cardiological evaluation

06

What researchers measure

Primary outcomes

  1. Atrial fibrillation

    New onset of Atrial Fibrillation documented at ECG

    Time frame: 10 years

Secondary outcomes

  1. Thromboembolism

    Stroke or peripheral embolization

    Time frame: 10 years

  2. Epicardial adipose tissue

    Thickness of fat depot in epicardial region

    Time frame: Baseline

  3. SGLT2 effect on Hb

    rise in hemoblogin levels

    Time frame: 6 months

  4. Atrial fibrillation recurrences

    Recurrences of AF during follow-up

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • Matteo Bertini
    Ferrara, Italy
    Recruiting
08

References and documents

Publications

  • Marchini F, Mele M, Marchetti E, Rotondo L, Frascaro F, Malagu M, Pavasini R, Tonet E, Serenelli M, Cossu A, Longo F, Lo Monaco M, Bertella E, Campo G, Bertini M. Assessing Cardiac Mechanical Dysfunction in Transfusion-Dependent beta-Thalassemia With History of Atrial Fibrillation: The Role of Speckle Tracking Echocardiography. Echocardiography. 2026 Feb;43(2):e70408. doi: 10.1111/echo.70408. PubMed 41674122 ↗
  • Malagu M, Marchini F, Longo F, Zuin M, Orazio G, Capanni A, Berloni ML, Frascaro F, Tonet E, Cossu A, Culcasi M, Bonsi B, Balla C, Vitali F, Bertini M. Association between epicardial adipose tissue and transfusion-dependent beta-thalassemia. Int J Cardiovasc Imaging. 2025 Nov;41(11):2255-2263. doi: 10.1007/s10554-025-03535-2. Epub 2025 Oct 9. PubMed 41065927 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Jun 2032, 117 months after the start.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 117 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2022
First posted
Aug 19, 2022
StartActual
Sep 1, 2022
Primary completionEst.
Jun 1, 2032
CompletionEst.
Jul 1, 2032
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05508932
Responsible party
Matteo Bertini (Associate Professor, University Hospital of Ferrara) — Principal investigator
First posted
Aug 19, 2022
Start date
Sep 1, 2022
Primary completion
Jun 1, 2032 (estimated)
Completion
Jul 1, 2032 (estimated)
Last update
Feb 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion